Allergan's Assets Could Diversify Pfizer's Neurology Portfolio

If Pfizer Inc. were to buy Allergan plc – or vice versa – the merged companies would have a large and actually quite diverse portfolio of drugs for central nervous system (CNS) diseases and conditions.